2022 年第 12 期 第 17 卷

安罗替尼导致可逆性后部脑病综合征1例及文献回顾

Anlotinib-induced posterior reversible encephalopathy syndrome: a case report and literature review

作者：陈妤 王琰 宋琳琳 张向阳 陈旭岩

英文作者：Chen Yu Wang Yan Song Linlin Zhang Xiangyang Chen Xuyan

单位：清华大学附属北京清华长庚医院急诊科清华大学临床医学院，北京102218

英文单位：Department of Emergency Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University School of Clinical Medicine Tsinghua University Beijing 102218 China

关键词：可逆性后部脑病综合征；安罗替尼；酪氨酸激酶抑制剂

英文关键词：Posteriorreversibleencephalopathysyndrome;Anlotinib;Tyrosinekinaseinhibitors

• 摘要：

• 可逆性后部脑病综合征（PRES）是一种亚急性神经系统综合征，主要表现为头痛、皮质盲及癫痫发作。但其病因复杂，发病机制不详，经常难以准确判断。目前已有文献报道多种靶向药物可以导致PRES，如贝伐珠单抗、索拉非尼。安罗替尼是我国自主研发的一种口服多靶点酪氨酸激酶抑制剂，临床研究已经证实，安罗替尼在肺癌、甲状腺髓样癌及肾细胞癌等多种恶性肿瘤的治疗中可改善患者生存预后。在对安罗替尼的不良反应监测中，安罗替尼相关的PRES少见报道。本文报道1例由安罗替尼诱发的PRES，并对相关文献进行复习，以提高临床医师对于该病的认识。

• Posterior reversible encephalopathy syndrome(PRES) is a subacute neurological syndrome characterized by headache, cortical blindness and seizures. However, the etiology is complex, the pathogenesis is unknown, and it is often difficult to accurately judge. At present, it has been reported that a variety of targeted drugs can cause PRES, such as bevacizumab and sorafenib. Anlotinib is an oral multi-target tyrosine kinase inhibitor independently developed in China. Clinical studies have confirmed that anlotinib can improve patients′ survival in the treatment of lung cancer, medullary thyroid cancer, renal cell carcinoma and other malignant tumors. Anlotinib-related PRES were rarely reported in the monitoring of adverse reactions. This article reports a case of anlotinib-induced PRES, and reviews the relevant literatures to improve clinicians′ understanding of this disease.